A design prototype by Datopian, not an official website
Find a Commonwealth ResourceHealthData.Gov
The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study was the first trial to assess whether statins might be of clinical benefit in those with recently unstable coronary disease. MIRACL…
Updated Oct 29, 2026
HealthData.Gov
Inhibition of the sodium-hydrogen exchanger (NHE) is a powerful experimental tool to inhibit sodium and calcium accumulation within the ischemic myocyte and halt progression of cell ischemia to cell necrosis. This paper…
Updated Oct 29, 2026
HealthData.Gov
Background The peroxisome proliferator-activated receptor α (PPARα) plays an important role in the metabolism of lipoproteins and fatty acids, and seems to protect against the development of atherosclerosis. To evaluate…
Updated Oct 29, 2026
HealthData.Gov
Objective To assess the effects of a 6-month angiotensin-converting enzyme (ACE) inhibitor intervention on myocardial ischaemia. Method We randomized 389 patients with stable coronary artery disease to double-blind…
Updated Oct 29, 2026
HealthData.Gov
The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) Trial tested the hypothesis that intensive lowering of cholesterol with atorvastatin (80 mg/day) initiated 24-96 h after an acute coronary…
Updated Oct 29, 2026
HealthData.Gov
During the past decade considerable research has been conducted into the use of cardiac troponins, their diagnostic capability and their potential to allow risk stratification in patients with acute chest pain.…
Updated Oct 29, 2026
HealthData.Gov
Background These studies investigate the role of mitoKATP channels, protein kinase C (PKC) and Mitogen activated protein kinase (p38MAPK) on the cardioprotection of ischemic (IP) and pharmacological preconditioning (PP)…
Updated Oct 29, 2026
